References
- Burnett AL. Rule of nitric oxide in the physiology of erection. Biol Reprod 1995; 52(3):485–9
- Nadig P. Office assessment of BPH, abnormal PSA/DRE and impotence using existing guidelines and proper CPT coding. American Urological Assoc Postgraduate Course. San Francisco, 1994
References
- Feldman HA, Goldstein I, Hatzichris-tou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54–61
- Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2): 47–52
- Goldstein I, Lue TF, Padma-Nathan H, et al, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20): 1397–404
- Morales A, Condra M, Owen JA, et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987; 137(6): 1168–72
- Randrup E, Wilson S, Mobley D, et al. Clinical experience with Mentor Alpha I inflatable penile prosthesis: report on 333 cases. Urology 1993; 42(3): 305–8
- Linet OI, Ogrinc FG, for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334(14): 873–7
- Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al, for the Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336(1): 1–7
- Govier FE, Jonsson E, Kramer-Levien D. Oral terbutaline for the treatment of priapism. J Urol 1994; 151(4): 878–9
- Becker AJ, Stief CG, Machtens S, et al. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998; 159(4): 1214–6
- Heaton JP, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45(2): 200–6